Comprehensive Stock Comparison
Compare XOMA Royalty Corp. (XOMA) vs BiomX Inc. (PHGE) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  XOMA | Beta 0.82 vs PHGE's 0.93 |
| Dividends | XOMA | 1.8% yield; PHGE pays no meaningful dividend |
| Momentum (1Y) | XOMA | +22.5% vs PHGE's -48.8% |
| Efficiency (ROA) | XOMA | 7.3% ROA vs PHGE's -142.8%, ROIC -37.6% vs -305.2% |
Who Each Stock Is For
Income & stability
XOMADividend streak 0 yrs, beta 0.82, yield 1.8%
Growth exposure
PHGEEPS growth 71.2%
Long-term compounding (10Y)
XOMA46.9% 10Y total return vs PHGE's -99.7%
Sleep-well-at-night portfolio
XOMALower volatility, beta 0.82, current ratio 5.15x
Defensive / Recession hedge
XOMABeta 0.82, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
XOMA Royalty Corp is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets—typically earning a percentage of future drug sales if the therapies succeed. The company's moat lies in its specialized expertise in evaluating clinical-stage assets and structuring royalty agreements that provide diversified exposure to potential blockbuster drugs without bearing development costs.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
XOMA 5PHGE 0XOMA1/1 metricsXOMA2/2 metricsXOMA6/9 metricsXOMA5/6 metricsXOMA2/2 metricsXOMA leads in 5 of 6 categories — strongest in Financial Metrics and Valuation Metrics.
Financial Metrics (TTM)
XOMA and PHGE operate at a comparable scale, with $47M and $0 in trailing revenue.
| Metric | XOMAXOMA Royalty Corp. | PHGEBiomX Inc. |
|---|---|---|
| RevenueTrailing 12 months | $47M | $0 |
| EBITDAEarnings before interest/tax | $22M | -$6M |
| Net IncomeAfter-tax profit | $19M | -$37M |
| Free Cash FlowCash after capex | $5M | -$28M |
| Gross MarginGross profit ÷ Revenue | +93.8% | — |
| Operating MarginEBIT ÷ Revenue | +4.1% | — |
| Net MarginNet income ÷ Revenue | +41.1% | — |
| FCF MarginFCF ÷ Revenue | +11.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +144.0% | -6.5% |
Valuation Metrics
| Metric | XOMAXOMA Royalty Corp. | PHGEBiomX Inc. |
|---|---|---|
| Market CapShares × price | $316M | $82.8B |
| Enterprise ValueMkt cap + debt − cash | $334M | $82.8B |
| Trailing P/EPrice ÷ TTM EPS | -16.03x | -4.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 39.71x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 11.10x | — |
| Price / BookPrice ÷ Book value/share | 3.78x | 3427.64x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
XOMA delivers a 17.9% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-4 for PHGE. PHGE carries lower financial leverage with a 0.40x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMA's 1.46x. On the Piotroski fundamental quality scale (0–9), XOMA scores 4/9 vs PHGE's 3/9, reflecting mixed financial health.
| Metric | XOMAXOMA Royalty Corp. | PHGEBiomX Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +17.9% | -3.6% |
| ROA (TTM)Return on assets | +7.3% | -142.8% |
| ROICReturn on invested capital | -37.6% | -3.1% |
| ROCEReturn on capital employed | -19.4% | -159.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 1.46x | 0.40x |
| Net DebtTotal debt minus cash | $18M | -$8M |
| Cash & Equiv.Liquid assets | $102M | $18M |
| Total DebtShort + long-term debt | $119M | $10M |
| Interest CoverageEBIT ÷ Interest expense | 0.67x | -36.86x |
Total Returns (with DRIP)
A $10,000 investment in XOMA five years ago would be worth $7,158 today (with dividends reinvested), compared to $47 for PHGE. Over the past 12 months, XOMA leads with a +22.5% total return vs PHGE's -48.8%. The 3-year compound annual growth rate (CAGR) favors XOMA at 7.4% vs PHGE's -59.1% — a key indicator of consistent wealth creation.
| Metric | XOMAXOMA Royalty Corp. | PHGEBiomX Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -5.5% | +194.4% |
| 1-Year ReturnPast 12 months | +22.5% | -48.8% |
| 3-Year ReturnCumulative with dividends | +23.9% | -93.2% |
| 5-Year ReturnCumulative with dividends | -28.4% | -99.5% |
| 10-Year ReturnCumulative with dividends | +46.9% | -99.7% |
| CAGR (3Y)Annualised 3-year return | +7.4% | -59.1% |
Risk & Volatility
XOMA is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than PHGE's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XOMA currently trades 66.3% from its 52-week high vs PHGE's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XOMAXOMA Royalty Corp. | PHGEBiomX Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 0.93x |
| 52-Week HighHighest price in past year | $39.92 | $14.71 |
| 52-Week LowLowest price in past year | $18.35 | $1.56 |
| % of 52W HighCurrent price vs 52-week peak | +66.3% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 49.0 | 51.0 |
| Avg Volume (50D)Average daily shares traded | 482K | 1.3M |
Analyst Outlook
XOMA is the only dividend payer here at 1.77% yield — a key consideration for income-focused portfolios.
| Metric | XOMAXOMA Royalty Corp. | PHGEBiomX Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $68.25 | — |
| # AnalystsCovering analysts | 10 | — |
| Dividend YieldAnnual dividend ÷ price | +1.8% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.47 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | 100 | 113.81 | +13.8% |
| BiomX Inc. (PHGE) | 100 | 0.23 | -99.8% |
XOMA Royalty Corp. (XOMA) returned -28% over 5 years vs BiomX Inc. (PHGE)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | $55M | $28M | -48.6% |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
XOMA Royalty Corp.'s revenue grew from $55M (2015) to $28M (2024) — a -7.1% CAGR.
Chart 3P/E Ratio History — 3 Years
| Stock | 2017 | 2021 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | 48.8 | 32.1 | -34.2% |
XOMA Royalty Corp. has traded in a 32x–57x P/E range over 3 years; current trailing P/E is ~-16x.
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | -3.5 | -1.65 | +52.9% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
XOMA Royalty Corp.'s EPS grew from $-3.50 (2015) to $-1.65 (2024).
Chart 5Free Cash Flow — 5 Years
XOMA Royalty Corp. generated $-14M FCF in 2024 (-260% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
XOMA vs PHGE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is XOMA or PHGE a better buy right now?
Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XOMA or PHGE?
Over the past 5 years, XOMA Royalty Corp. (XOMA) delivered a total return of -28.4%, compared to -99.5% for BiomX Inc. (PHGE). A $10,000 investment in XOMA five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: XOMA returned +46.9% versus PHGE's -99.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XOMA or PHGE?
By beta (market sensitivity over 5 years), XOMA Royalty Corp. (XOMA) is the lower-risk stock at 0.82β versus BiomX Inc.'s 0.93β — meaning PHGE is approximately 13% more volatile than XOMA relative to the S&P 500. On balance sheet safety, BiomX Inc. (PHGE) carries a lower debt/equity ratio of 40% versus 146% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.
04Which has better profit margins — XOMA or PHGE?
BiomX Inc. (PHGE) is the more profitable company, earning 0.0% net margin versus -48.5% for XOMA Royalty Corp. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -140.3% for XOMA. At the gross margin level — before operating expenses — XOMA leads at 99.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — XOMA or PHGE?
In this comparison, XOMA (1.8% yield) pays a dividend. PHGE does not pay a meaningful dividend and should not be held primarily for income.
06Is XOMA or PHGE better for a retirement portfolio?
For long-horizon retirement investors, XOMA Royalty Corp. (XOMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.82), 1.8% yield). Both have compounded well over 10 years (XOMA: +46.9%, PHGE: -99.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between XOMA and PHGE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. XOMA pays a dividend while PHGE does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.